case_images: PMC4000298_01
case_images: Integrated display of therapy and assessments performed. The various assessments used in managing this case are displayed. Each symbol represents an assessment:   = CTC count;   = CA 27.29 determination;   = CEA determinations. The time point of each PET/CT imaging assessment is shown as a two-letter code with an arrow below: PD = progressive disease; PR = partial response; MR = mixed response. Boxes representing the duration of each treatment are shown across the top of the graph with the name of the therapeutic regimen. The arrow labeled IR indicates the time frame when radiation treatment was given. Bev = Bevacizumab.
case_images: cro-0007-0175-g01.jpg
case_images: PMC4000298_01_cro-0007-0175-g01.jpg
case_images: F1
case_images: An initial CTC measurement using the CELLSEARCH  System resulted in a determination of 1/7.5 ml (fig. 1). Repeat imaging in July 2007 showed a partial response (PR) in the liver and bone lesions (fig. 1). PET/CT imaging demonstrated improvement in the liver lesions and a mixed response in the bone lesions (fig. 1). Her CTC level had risen from 0 in April to 9/7.5 ml, and CA 27.29 had risen to 1,371 U/ml, confirming progressive disease (fig. 1).